A genetically engineered herpes virus can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action against tumours, a landmark clinical trial has shown.
It is the first time that a Phase III trial of viral immunotherapy has definitively shown benefit for patients with cancer.
The trial was led in the UK by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 64 research centres worldwide, including the University of Oxford.
Researchers randomised 436 patients with aggressive, inoperable malignant melanoma to receive either an injection of the viral therapy, called Talimogene Laherparepvec, or a control immunotherapy.
Some 16.3% of the group given Talimogene Laherparepvec – known as T-VEC – showed a durable treatment response of more than six months, compared with 2.1% given the control treatment.
Some patients had a response extending past three years, a mark oncologists often use as a proxy for cure in immunotherapy.
Importantly, responses to treatment were most pronounced in patients with less advanced cancers (stage IIIB, IIIC, IVM1a) and those who had yet to receive any treatment – underlining the potential benefits of T-VEC as a first-line treatment for metastatic melanoma which cannot be surgically removed.
Patients with stage III and early stage IV melanoma treated with T-VEC – a total of 163 people – lived an average of 41 months. This compared with an average survival of 21.5 months in the 66 earlier-stage patients who received the control immunotherapy.
The trial was funded by the manufacturer of T-VEC, Amgen, and is published in the Journal of Clinical Oncology.
T-VEC is a modified form of herpes simplex virus type-1 which multiplies inside cancer cells and bursts them from within. It has been genetically engineered to produce a molecule called GM-CSF, which stimulates the immune system to attack and destroy the tumour.
T-VEC is one of a new wave of virus-based drugs to show benefits in cancer trials, and is now the first to do so in a major randomised, controlled Phase III trial.
The virus has been modified to remove two key genes, called ICP34.5 and ICP47, so that it can’t replicate within healthy cells. Normal cells detect and destroy T-VEC before it can cause damage – but it replicates easily in cancer cells because their infection defences are compromised by genetic errors.
UK trial leader Professor Kevin Harrington, Professor of Biological Cancer Therapies at the ICR and Honorary Consultant at The Royal Marsden, said: “There is increasing excitement over the use of viral treatments like T-VEC for cancer, because they can launch a two-pronged attack on tumours – both killing cancer cells directly and marshalling the immune system against them. And because viral treatment can target cancer cells specifically, it tends to have fewer side-effects than traditional chemotherapy or some of the other new immunotherapies.
“Our study showed that T-VEC can deliver a significant, durable benefit for people with melanoma. It is encouraging that the treatment had such a clear benefit for patients with less advanced cancers – ongoing studies are evaluating if it can become a first-line treatment for more aggressive melanomas and advanced disease.”
The Latest on: Viral immunotherapy
via Google News
The Latest on: Viral immunotherapy
- The Role of Immunotherapy in Treating R/R mHCCon September 6, 2019 at 12:16 pm
So your sustained viral response rates to hepatitis C therapy are significantly ... re talking about any cancer—but we have to talk about checkpoint inhibitors and immunotherapy [I/O]. But it’s super ...
- Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptomeon September 2, 2019 at 2:12 am
Loss of NK cells renders patients prone to viral infection, especially herpes viruses 3. NK cells have proven to be safe and effective mediators of cellular immunotherapy 4,5. Despite their clinical ...
- ISA Pharmaceuticals Strengthens its Supervisory Board with the Addition of Dr. Markwin Velderson September 2, 2019 at 1:04 am
(live-PR.com) - Leiden, The Netherlands, September 02, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and ...
- Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunitieson August 28, 2019 at 11:01 pm
About GEN-1 Immunotherapy GEN-1, designed using Celsion's proprietary TheraPlas platform technology, is an IL-12 DNA plasmid vector encased in a synthetic, non-viral, nanoparticle delivery system ...
- Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference Nasdaq:ATRAon August 28, 2019 at 9:15 pm
allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon, the Company's President and Chief ...
- Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conferenceon August 28, 2019 at 2:05 am
Aug. 28, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, ...
- Global Liver Cancer Treatment Market is Expected to Reach USD 2,186.63 Million by 2025 : Fior Marketson August 27, 2019 at 3:26 am
Certain medical conditions such as Hepatitis B and C viral infections ... Growing use of immunotherapy drugs in the combination drug treatments is leading major drug manufacturers to develop ...
- Virotherapy Treatment for Mesothelioma Patientson August 22, 2019 at 5:00 pm
Virotherapy is a cancer treatment that uses oncolytic viruses and viral immunotherapy to destroy cancer cells directly or trigger the immune system to find and kill cancer cells. Clinical trials are ...
- Oncorus Adds $79.5M to Steer Cancer-Fighting Virus to Human Testingon August 21, 2019 at 4:06 am
These cells deaths lead to the immunotherapy step of the treatment ... ONCR-177 partially or completely shrunk tumors, and the viral therapy led to protective immunity. Ashburn adds that the ...
- New T cell detection method promises personalized immunotherapy for melanomason August 10, 2019 at 8:41 pm
Their capabilities are therefore crucial in the immune response to viral infections and tumors. When immunotherapy is used to treat some cancers, the aim is to stimulate the T cells in the patient’s ...
via Bing News